In a letter to Senate Leaders Schumer and McConnell on the current version of a reconciliation package including prescription drug reform provisions, ACCC expressed concerns about the impact of Medicare drug price negotiation on Part B drug reimbursement. As proposed, these reimbursement cuts would significantly reduce beneficiary access to crucial medications and treatments and also threaten the financial viability of cancer programs and practices. ACCC encourages Congress to seek alternative solutions to reduce prescription drug costs that hold providers harmless.
